Results 61 to 70 of about 28,272 (264)

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Lipids, EarlyView.
ABSTRACT Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering
Chao Zhao, Nuan Wang, Di Shi, Hao Zhou, Dan Chen, Guofang Chen   +5 more
wiley   +1 more source

Evaluation of adropin indices and PCSK9 in non-diabetic men with severe obstructive sleep apnea

Türk Biyokimya Dergisi
We aimed to investigate the relationship among proprotein convertase subtilisin/kexin type 9 (PCSK9), adropin levels, inflammation, and sleep variables in non-diabetic males with severe obstructive sleep apnea (OSA).
Deniz Levent, Aral Hale, Akdoğan Özlem, Arslan Hilmi Furkan, Yiğit Enes   +4 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations

Frontiers in Pharmacology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily secreted by hepatocytes. PCSK9 is critical in liver low-density lipoprotein receptors (LDLRs) metabolism.
Fengyuan Lu, En Li, Xiaoyu Yang, Xiaoyu Yang   +3 more
doaj   +1 more source

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis

Journal of Community Hospital Internal Medicine Perspectives, 2020
Background Proprotein convertase subtilisin/Kexin type 9 (PCSK-9) inhibitors induced liver dysfunction in patients with or without previous liver injury, and this is not well discussed in the previous literature.
Yousuf Zafar, Yasar Sattar, Waqas Ullah, Sohaib Roomi, Mamoon-Ur- Rashid, Muhammad Shayan Khan, Laura Schmidt   +6 more
doaj   +1 more source

The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure:BIOSTAT-CHF Subanalysis [PDF]

, 2017
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein receptor (LDLR), preventing its recycling. PCSK9 is a risk predictor and a biotarget in atherosclerosis progression.
Anker, Stefan D., Bayes-Genis, Antoni, Cleland, John G. F., Dickstein, Kenneth, Ferreira, João Pedro, Filippatos, Gerasimos S., Lang, Chim C., Lupón, Josep, Metra, Marco, Ng, Leong, Núñez, Julio, Ponikowski, Piotr, Samani, Nilesh J., van Veldhuisen, Dirk J., Voors, Adriaan A., Zannad, Faiez, Zwinderman, Aeilko H.   +16 more
core   +4 more sources

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9

Frontiers in Physiology, 2020
Neuronal apoptosis regulated convertase-1 (NARC-1), now mostly known as proprotein convertase subtilisin/kexin type 9 (PCSK9), has received a lot of attention due to the fact that it is a key regulator of the low-density lipoprotein (LDL) receptor (LDL-R)
Klaus-Dieter Schlüter, Annemarie Wolf, Rolf Schreckenberg   +2 more
doaj   +1 more source

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9 [PDF]

Journal of Thoracic Disease, 2017
Lipoprotein(a) [Lp(a)] has been identified as a risk factor for cardiovascular disease. Lp(a) levels are also high under certain clinical conditions, including familial hypercholesterolemia and high blood low-density lipoprotein (LDL) cholesterol levels. Few effective generic therapies for modulating Lp(a) have been developed.
Kazuhiko, Kotani, Maciej, Banach
openaire   +2 more sources

Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction

British Journal of Pharmacology, EarlyView.
Background and Purpose Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses.
Erik Klapproth, Johanna Marks, Patrick Diaba‐Nuhoho, Sören Grell, Paul Leubauer, Susanne Kämmerer, Johannes R. Soltwedel, Fred Rasmussen, Felix Mejia, Marcia L. Moss, Christopher Prince, Peter Mirtschink, Ben Wielockx, Paul Saftig, Michael Wagner, Kristina Lorenz, Ali El‐Armouche   +16 more
wiley   +1 more source

Childhood Obesity and Familial Hypercholesterolemia: Genetic Diseases that Contribute to Cardiovascular Disease [PDF]

, 2014
Childhood obesity occurs as the result of an imbalance between caloric intake and energy expenditure. Genetic risk factors for obesity have become an area of research due to its permanency.
Caudle, Alyssa
core   +1 more source